Philadelphia Defective Product Lawyers

More information on Cervical Cancer Vaccine:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Cervical Cancer Vaccine:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Cervical Cancer Vaccine:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More (12/20/11) relevant Information for Cervical Cancer Vaccine:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.
• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.
• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.
• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.
• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

http://www.seedol.com

More information on Gardasil Anaphylaxis:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Anaphylaxis:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Gardasil Anaphylaxis

More (12/20/11) on Gardasil Anaphylaxis:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Gardasil Anaphylaxis:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.

• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.

• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.

• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.

• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

http://www.seedol.com

Actos Lawyer 12/21/2011: The urethra is a hollow tube lined with transitional cells at its beginning that connects the bladder to the outside world. The structure of the urethra is different in men and women. The urethra is short in women and is much longer in men due to the presence of the penis. The cells lining the urethra change along its length. The inner cells, closest to the bladder, are transitional cells, whereas the cells closest to the outside of the body are squamous cells resembling skin. Although the urethra has different lengths in men and women, it functions the same. In men, the urethra passes through the prostate gland near the bladder.

Foe more information on Actos Lawyer follow us on our RSS Feeds.

Our use of the Terms Actos Bladder Cancer, Actos Attorneys is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Acts. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Attorney12/15/2011: Bleeding is usually present, but rarely severe. Some tumors are more vascular than others and will bleed more. In addition, the resection will involve the bladder wall and vascularity varies here as well. Transfusions are not generally required unless an individual starts with a low blood count from previous bleeding or medical condition. Bleeding can be an on going concern until the bladder completely heals weeks later. Catheterization and irrigation may be required. Just a small amount of blood will change the color of urine red. Urine that is punch colored or the color of rosé wine generally is not serious and will clear on its own. When the urine has large amounts of blood in it, the appearance generally looks like tomato juice, indicating serious bleeding requiring medical attention.

For more information on Actos Attorneys follow us on our RSS Feeds.

Our use of the Terms Actos FDA Recall, Actos Litigation is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Attorney 12/15/2011: A catheter is a plastic or rubber tube which is placed through the urethra into the bladder. It is kept in place by a fluid filled balloon, at the end of the catheter, which is inflated in the bladder. The tube allows for drainage of urine which may be mixed with blood after a TURBT. When small tumors are removed, a catheter is not usually required unless there is a concern that you may have difficulty urinating after the procedure because of an enlarged prostate, weak bladder or swelling of the urethra after instrumentation. After large tumors are resected, a catheter is often required.

For more information on Actos Attorney follow us on our RSS Feeds.

Our use of the Terms Actos Lawyers, Actos and Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos and Bladder Cancer 12/20/2011: After several courses of chemotherapy, an assessment of your clinical progress will be made. This will generally require a study such as a CAT scan, to check the response of the cancer to the chemotherapy. If progress is being made and the individual is tolerating the chemotherapy, a decision is then made to continue the chemotherapy to completion. If on the other hand, the cancer is not responding or the individual is not tolerating the therapy, a decision can be made to stop further chemotherapy, alter the present regimen, or try a different course of chemotherapy.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuits , Actos Bladder Cancer Lawyer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Bladder Cancer12/20/2011: This brief review undermines the uncertainty of receiving chemotherapy during an experimental protocol. If the individual needs chemotherapy, it is generally safer and wiser to receive the standard regimen already established as safe and possibly effective. If however, prior standard chemotherapy has proven to be ineffective, or if the patient cannot tolerate standard therapy and the patient’s health allows for additional chemo, enrollment in a chemotherapy trial may be appropriate if the individual qualifies. At times, there can be breakthroughs and new agents can be more effective in eradicating cancer than the established drugs.

For more information on Actos Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Warning, Side Effects of Actos is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Lawsuit 12/21/2011: The American Cancer Society estimates that in 2006,61,420 new cases of bladder cancer were diagnosed in the United States with approximately 73% of those occurring in men. In the same year, this cancer caused approximately 13,060 deaths with approximately two out of three of those being in men. The disease is more common in whites than blacks. The incidence of bladder cancer increases with age in both sexes. When bladder cancer occurs in young people, it tends to grow slower and not be as serious. In men, it is the fourth most common cancer. However, because of the rate of recurrences and long term survival, it is the second most prevalent cancer in middle aged and elderly men. In women, it is the eighth most common cancer. The average age at diagnosis is 65. Over the past decade, there has been both an increased incidence, but also an increased rate of survival for bladder cancer.

For more information on Actos Lawsuit follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuit , Actos Bladder Cancer Lawyer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com